Capital meets innovation: AusBiotech Invest Perth 2026 underway

Tuesday 19 May 2026

AusBiotech Invest Perth 2026 opens its doors today at the Crown Towers, bringing together investors, life sciences companies and global partners focused on the next generation of breakthroughs.
Australia's biotechnology and medical technology sector has seen remarkable growth, now counting close to 1,600 companies — twice as many as there were eight years ago.
AusBiotech Director of Investment, Kerri Lee Sinclair, said AusBiotech Invest Perth 2026 is designed to connect serious science with serious capital and to foster the disciplined, direct conversations the current market demands.
"In today's market, company readiness, evidence quality, commercial clarity and strategic investor engagement are increasingly important to how life sciences companies attract capital and build credibility and progress towards commercial and clinical milestones.
"For 40 years, AusBiotech has supported the sector's growth. Our always-on investment programs, including AusBiotech Invest, are designed to strengthen the conditions for long-term investment by improving company readiness, increasing the visibility of high-quality opportunities, and supporting more effective investor engagement.
"Today is a strong example of that work in action. The quality of investors, companies and partners in the room highlights the importance of creating the right settings to build credibility, attract investment and grow globally."
Presenting companies include Tessara Therapeutics, PredicTx Health, Cytophenix, VeinTech, Marine Biomedical and Humble Bee Bio, representing a cross-section of Australian and New Zealand life sciences companies building investor-relevant opportunities across therapeutics, diagnostics, medtech and platform technologies.
Throughout the day, the program connects investor perspectives, company showcases and scaling stories to examine what it takes for Australian life sciences companies to navigate today’s market and grow into globally relevant businesses. For full program details and speaker information, visit: https://ausbiotechinvest.com/register/
ENDS
Media inquiries:
Rose Petrass, AusBiotech Communications Advisor / +61 0457 867 780 / [email protected]
About AusBiotech
AusBiotech is Australia's leading national and global advocate for life sciences, working to help its more than 3500 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.